Jouni Hirvonen

List of Publications by Year
in descending order

175	11,978	18482 62	31849 101
papers	citations	h-index	g-index

176	176	176	12883
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantitative Analysis of Porous Silicon Nanoparticles Functionalization by ¹H NMR. ACS Biomaterials Science and Engineering, 2022, 8, 4132-4139.	5.2	5
2	Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. Bioactive Materials, 2022, 9, 299-315.	15.6	23
3	In Vitro Evaluation of the Therapeutic Effects of Dualâ€Drug Loaded Spermineâ€Acetalated Dextran Nanoparticles Coated with Tannic Acid for Cardiac Applications. Advanced Functional Materials, 2022, 32, 2109032.	14.9	13
4	High drug-loaded microspheres enabled by controlled in-droplet precipitation promote functional recovery after spinal cord injury. Nature Communications, 2022, 13, 1262.	12.8	39
5	Microfluidics Fabrication of Micrometerâ€Sized Hydrogels with Precisely Controlled Geometries for Biomedical Applications. Advanced Healthcare Materials, 2022, 11, .	7.6	22
6	Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. Acta Biomaterialia, 2021, 133, 231-243.	8.3	72
7	Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 254-265.	4.3	13
8	Prospective Cancer Therapies Using Stimuliâ€Responsive DNA Nanostructures. Macromolecular Bioscience, 2021, 21, e2100272.	4.1	15
9	Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke. Biomaterials, 2020, 227, 119556.	11.4	23
10	Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction. Nanoscale, 2020, 12, 2350-2358.	5.6	42
11	Hybrid red blood cell membrane coated porous silicon nanoparticles functionalized with cancer antigen induce depletion of T cells. RSC Advances, 2020, 10, 35198-35205.	3.6	10
12	Nanosuspensions of a poorly soluble investigational molecule ODM-106: Impact of milling bead diameter and stabilizer concentration. International Journal of Pharmaceutics, 2020, 587, 119636.	5.2	22
13	Spray-drying for the formulation of oral drug delivery systems. , 2020, , 253-284.		6
14	Superfast and controllable microfluidic inking of anti-inflammatory melanin-like nanoparticles inspired by cephalopods. Materials Horizons, 2020, 7, 1573-1580.	12.2	16
15	Multifunctional 3Dâ€Printed Patches for Longâ€Term Drug Release Therapies after Myocardial Infarction. Advanced Functional Materials, 2020, 30, 2003440.	14.9	53
16	Tandemâ€Massâ€Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition. Advanced Science, 2020, 7, 2001129.	11.2	11
17	Principles of nanosized drug delivery systems. , 2020, , 3-25.		6
18	The versatile biomedical applications of bismuth-based nanoparticles and composites: therapeutic, diagnostic, biosensing, and regenerative properties. Chemical Society Reviews, 2020, 49, 1253-1321.	38.1	261

#	Article	IF	Citations
19	Fabrication and Characterization of Drug-Loaded Conductive Poly(glycerol) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 747 Td (sebac Materials & Interfaces, 2020, 12, 6899-6909.	8.0	57
20	Preparation and Characterization of Dentin Phosphophorynâ€Derived Peptideâ€Functionalized Lignin Nanoparticles for Enhanced Cellular Uptake. Small, 2019, 15, e1901427.	10.0	57
21	Drug nanocrystals â€“ Versatile option for formulation of poorly soluble materials. International Journal of Pharmaceutics, 2018, 537, 73-83.	5.2	103
22	Dualâ€Drug Delivery Using Dextranâ€Functionalized Nanoparticles Targeting Cardiac Fibroblasts for Cellular Reprogramming. Advanced Functional Materials, 2018, 28, 1705134.	14.9	60
23	Cardiac Actions of a Small Molecule Inhibitor Targeting GATA4â€“NKX2-5 Interaction. Scientific Reports, 2018, 8, 4611.	3.3	29
24	Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines. Advanced Healthcare Materials, 2018, 7, 1700432.	7.6	30
25	Conductive vancomycin-loaded mesoporous silica polypyrrole-based scaffolds for bone regeneration. International Journal of Pharmaceutics, 2018, 536, 241-250.	5.2	65
26	Microfluidic Nanoassembly of Bioengineered Chitosan-Modified FcRn-Targeted Porous Silicon Nanoparticles @ Hypromellose Acetate Succinate for Oral Delivery of Antidiabetic Peptides. ACS Applied Materials & Interfaces, 2018, 10, 44354-44367.	8.0	47
27	High-Generation Amphiphilic Janus-Dendrimers as Stabilizing Agents for Drug Suspensions. Biomacromolecules, 2018, 19, 3983-3993.	5.4	11
28	Engineered Multifunctional Albuminâ€Decorated Porous Silicon Nanoparticles for FcRn Translocation of Insulin. Small, 2018, 14, e1800462.	10.0	53
29	Analytical tools for reliable in vitro and in vivo performance testing of drug nanocrystals. , 2018, , 441-477.		2
30	The Emerging Role of Multifunctional Theranostic Materials in Cancer Nanomedicine. , 2018, , 1-31.		8
31	Impact of Pore Size and Surface Chemistry of Porous Silicon Particles and Structure of Phospholipids on Their Interactions. ACS Biomaterials Science and Engineering, 2018, 4, 2308-2313.	5.2	21
32	Biomimetic Engineering Using Cancer Cell Membranes for Designing Compartmentalized Nanoreactors with Organelleâ€Like Functions. Advanced Materials, 2017, 29, 1605375.	21.0	54
33	Core/Shell Nanocomposites Produced by Superfast Sequential Microfluidic Nanoprecipitation. Nano Letters, 2017, 17, 606-614.	9.1	123
34	InÂvitro evaluation of biodegradable lignin-based nanoparticles for drug delivery and enhanced antiproliferation effect in cancer cells. Biomaterials, 2017, 121, 97-108.	11.4	296
35	Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles. Journal of Controlled Release, 2017, 249, 111-122.	9.9	31
36	A Nanoâ€inâ€Nano Vector: Merging the Best of Polymeric Nanoparticles and Drug Nanocrystals. Advanced Functional Materials, 2017, 27, 1604508.	14.9	42

#	Article	IF	Citations
37	Surface modification of acetaminophen particles by atomic layer deposition. International Journal of Pharmaceutics, 2017, 525, 160-174.	5.2	40
38	A multifunctional nanocomplex for enhanced cell uptake, endosomal escape and improved cancer therapeutic effect. Nanomedicine, 2017, 12, 1401-1420.	3.3	15
39	A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging. ACS Applied Materials & Interfaces, 2017, 9, 13976-13987.	8.0	44
40	Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 403-405.	2.2	11
41	Quercetinâ€Based Modified Porous Silicon Nanoparticles for Enhanced Inhibition of Doxorubicinâ€Resistant Cancer Cells. Advanced Healthcare Materials, 2017, 6, 1601009.	7.6	49
42	Functionalization of carboxylated lignin nanoparticles for targeted and pH-responsive delivery of anticancer drugs. Nanomedicine, 2017, 12, 2581-2596.	3.3	96
43	Multifunctional Nanotubeâ€“Mucoadhesive Poly(methyl vinyl etherâ€coâ€maleic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Delivery. Advanced Healthcare Materials, 2017, 6, 1700629.	7.6	35
44	Drugâ€Loaded Multifunctional Nanoparticles Targeted to the Endocardial Layer of the Injured Heart Modulate Hypertrophic Signaling. Small, 2017, 13, 1701276.	10.0	82
45	Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy. Acta Biomaterialia, 2017, 48, 238-246.	8.3	109
46	Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-Î²-Cyclodextrin as a Solubilizer. Pharmaceutical Research, 2017, 34, 25-35.	3.5	17
47	Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1421.	6.1	72
48	Microfluidics platform for glass capillaries and its application in droplet and nanoparticle fabrication. International Journal of Pharmaceutics, 2017, 516, 100-105.	5.2	47
49	Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability. Pharmaceutics, 2016, 8, 16.	4.5	161
50	pHâ€Switch Nanoprecipitation of Polymeric Nanoparticles for Multimodal Cancer Targeting and Intracellular Triggered Delivery of Doxorubicin. Advanced Healthcare Materials, 2016, 5, 1904-1916.	7.6	44
51	Thiolation and Cellâ€Penetrating Peptide Surface Functionalization of Porous Silicon Nanoparticles for Oral Delivery of Insulin. Advanced Functional Materials, 2016, 26, 3405-3416.	14.9	94
52	Drug permeation and cellular interaction of amino acid-coated drug combination powders for pulmonary delivery. International Journal of Pharmaceutics, 2016, 504, 89-97.	5.2	13
53	Multifaceted polymersome platforms: Spanning from self-assembly to drug delivery and protocells. Progress in Polymer Science, 2016, 60, 51-85.	24.7	87
54	Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. Journal of Controlled Release, 2016, 232, 113-119.	9.9	44

#	Article	IF	Citations
55	Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. Journal of Controlled Release, 2016, 232, 29-41.	9.9	168
56	Influence of Surface Chemistry on Ibuprofen Adsorption and Confinement in Mesoporous Silicon Microparticles. Langmuir, 2016, 32, 13020-13029.	3.5	25
57	Microparticles to enhance delivery of drugs and growth factors into wound sites. Therapeutic Delivery, 2016, 7, 711-732.	2.2	13
58	Platelet Lysate-Modified Porous Silicon Microparticles for Enhanced Cell Proliferation in Wound Healing Applications. ACS Applied Materials & Interfaces, 2016, 8, 988-996.	8.0	33
59	Microfluidics as a cutting-edge technique for drug delivery applications. Journal of Drug Delivery Science and Technology, 2016, 34, 76-87.	3.0	75
60	Production, applications and inÂvivo fate of drug nanocrystals. Journal of Drug Delivery Science and Technology, 2016, 34, 21-31.	3.0	30
61	Onâ€Chip Selfâ€Assembly of a Smart Hybrid Nanocomposite for Antitumoral Applications. Advanced Functional Materials, 2015, 25, 1488-1497.	14.9	60
62	A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors. Nano Research, 2015, 8, 1505-1521.	10.4	54
63	Systematic inÂvitro and inÂvivo study on porous silicon to improve the oral bioavailability of celecoxib. Biomaterials, 2015, 52, 44-55.	11.4	38
64	Multistage pH-responsive mucoadhesive nanocarriers prepared by aerosol flow reactor technology: A controlled dual protein-drug delivery system. Biomaterials, 2015, 68, 9-20.	11.4	77
65	Inorganic Nanoparticles in Targeted Drug Delivery and Imaging. Advances in Delivery Science and Technology, 2015, , 571-613.	0.4	12
66	Solid formulations by a nanocrystal approach: Critical process parameters regarding scale-ability of nanocrystals for tableting applications. International Journal of Pharmaceutics, 2015, 485, 77-86.	5.2	24
67	Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells. ACS Applied Materials & Interfaces, 2015, 7, 23197-23204.	8.0	55
68	Safety and toxicity concerns of orally delivered nanoparticles as drug carriers. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 381-393.	3.3	38
69	Microfluidic assisted one-step fabrication of porous silicon@acetalated dextran nanocomposites for precisely controlled combination chemotherapy. Biomaterials, 2015, 39, 249-259.	11.4	133
70	Interaction Studies Between Indomethacin Nanocrystals and PEO/PPO Copolymer Stabilizers. Pharmaceutical Research, 2015, 32, 628-639.	3.5	38
71	In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 635-642.	4.3	25
72	Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo. International Journal of Pharmaceutics, 2014, 467, 34-41.	5.2	99

#	Article	IF	Citations
73	Poly(methyl vinyl etherâ€altâ€maleic acid)â€Functionalized Porous Silicon Nanoparticles for Enhanced Stability and Cellular Internalization. Macromolecular Rapid Communications, 2014, 35, 624-629.	3.9	42
74	Microfluidic Assembly of Monodisperse Multistage pHâ€Responsive Polymer/Porous Silicon Composites for Precisely Controlled Multiâ€Drug Delivery. Small, 2014, 10, 2029-2038.	10.0	105
75	Fabrication of a Multifunctional Nanoâ€inâ€micro Drug Delivery Platform by Microfluidic Templated Encapsulation of Porous Silicon in Polymer Matrix. Advanced Materials, 2014, 26, 4497-4503.	21.0	138
76	Nanocrystal-based per-oral itraconazole delivery: Superior in vitro dissolution enhancement versus SporanoxÂ® is not realized in in vivo drug absorption. Journal of Controlled Release, 2014, 180, 109-116.	9.9	63
77	Microfluidic assembly of multistage porous siliconâ€“lipid vesicles for controlled drug release. Lab on A Chip, 2014, 14, 1083-1086.	6.0	75
78	Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors. Nanoscale, 2014, 6, 10377-10387.	5.6	108
79	Controlled transdermal delivery of leuprorelin by pulsed iontophoresis and ion-exchange fiber. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 594-601.	4.3	14
80	Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications. Nanomedicine, 2014, 9, 535-554.	3.3	155
81	Confinement Effects on Drugs in Thermally Hydrocarbonized Porous Silicon. Langmuir, 2014, 30, 2196-2205.	3.5	30
82	SVM Classification and CoMSIA Modeling of UGT1A6 Interacting Molecules. Journal of Chemical Information and Modeling, 2014, 54, 1011-1026.	5.4	11
83	Mesoporous Materials and Nanocrystals for Enhancing the Dissolution Behavior of Poorly Water-soluble Drugs. Current Pharmaceutical Biotechnology, 2014, 14, 926-938.	1.6	24
84	Ion-exchange and iontophoresis-controlled delivery of apomorphine. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 477-484.	4.3	16
85	Inhibition of Influenza A Virus Infection in Vitro by Saliphenylhalamide-Loaded Porous Silicon Nanoparticles. ACS Nano, 2013, 7, 6884-6893.	14.6	71
86	Evaluation of drug interactions with nanofibrillar cellulose. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1238-1244.	4.3	52
87	Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. Journal of Controlled Release, 2013, 170, 268-278.	9.9	141
88	Dissolution Studies of Poorly Soluble Drug Nanosuspensions in Non-sink Conditions. AAPS PharmSciTech, 2013, 14, 748-756.	3.3	103
89	Dissolution study of nanocrystal powders of a poorly soluble drug by UV imaging and channel flow methods. European Journal of Pharmaceutical Sciences, 2013, 50, 511-519.	4.0	38
90	Drug release from nanoparticles embedded in four different nanofibrillar cellulose aerogels. European Journal of Pharmaceutical Sciences, 2013, 50, 69-77.	4.0	209

#	Article	IF	Citations
91	Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate. International Journal of Pharmaceutics, 2013, 441, 248-254.	5.2	22
92	Nanostructured Porous Siliconâ€Solid Lipid Nanocomposite: Towards Enhanced Cytocompatibility and Stability, Reduced Cellular Association, and Prolonged Drug Release. Advanced Functional Materials, 2013, 23, 1893-1902.	14.9	72
93	Microfluidic Templated Mesoporous Siliconâ€“Solid Lipid Microcomposites for Sustained Drug Delivery. ACS Applied Materials & Interfaces, 2013, 5, 12127-12134.	8.0	45
94	Nanostructured porous silicon in preclinical imaging: Moving from bench to bedside. Journal of Materials Research, 2013, 28, 152-164.	2.6	54
95	Porous Silicon Nanoparticles. , 2013, , 235-275.		1
96	Toxicological Profile of Therapeutic Nanodelivery Systems. Current Drug Metabolism, 2012, 13, 1068-1086.	1.2	39
97	Intravenous Delivery of Hydrophobin-Functionalized Porous Silicon Nanoparticles: Stability, Plasma Protein Adsorption and Biodistribution. Molecular Pharmaceutics, 2012, 9, 654-663.	4.6	146
98	Amine Modification of Thermally Carbonized Porous Silicon with Silane Coupling Chemistry. Langmuir, 2012, 28, 14045-14054.	3.5	108
99	New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 314-323.	4.3	37
100	Nanostructured porous silicon materials: potential candidates for improving drug delivery. Nanomedicine, 2012, 7, 1281-1284.	3.3	49
101	Nanofibrillar cellulose films for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 308-315.	4.3	220
102	Highly variable pH effects on the interaction of diclofenac and indomethacin with human UDP-glucuronosyltransferases. Toxicology in Vitro, 2012, 26, 1286-1293.	2.4	9
103	Cellular interactions of surface modified nanoporous silicon particles. Nanoscale, 2012, 4, 3184.	5.6	63
104	Tablet preformulations of indomethacin-loaded mesoporous silicon microparticles. International Journal of Pharmaceutics, 2012, 422, 125-131.	5.2	31
105	Spray-dried nanofibrillar cellulose microparticles for sustained drug release. International Journal of Pharmaceutics, 2012, 430, 47-55.	5.2	144
106	¹⁸F-Labeled Modified Porous Silicon Particles for Investigation of Drug Delivery Carrier Distribution in Vivo with Positron Emission Tomography. Molecular Pharmaceutics, 2011, 8, 1799-1806.	4.6	65
107	Spray-Dried Cellulose Nanofibers as Novel Tablet Excipient. AAPS PharmSciTech, 2011, 12, 1366-1373.	3.3	105
108	Immobilization of protein-coated drug nanoparticles in nanofibrillar cellulose matricesâ€”Enhanced stability and release. Journal of Controlled Release, 2011, 156, 390-397.	9.9	128

#	Article	IF	Citations
109	Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. International Journal of Pharmaceutics, 2011, 416, 242-51.	5.2	50
110	Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials, 2011, 32, 9089-9099.	11.4	71
111	Intact Nanoparticulate Indomethacin in Fast-Dissolving Carrier Particles by Combined Wet Milling and Aerosol Flow Reactor Methods. Pharmaceutical Research, 2011, 28, 2403-2411.	3.5	41
112	Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling. International Journal of Pharmaceutics, 2011, 411, 215-222.	5.2	181
113	Drug Delivery Formulations of Ordered and Nonordered Mesoporous Silica: Comparison of Three Drug Loading Methods. Journal of Pharmaceutical Sciences, 2011, 100, 3294-3306.	3.3	144
114	Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials, 2011, 32, 2625-2633.	11.4	157
115	Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. International Journal of Pharmaceutics, 2011, 414, 148-156.	5.2	124
116	Effects of Cell Differentiation and Assay Conditions on the UDP-Glucuronosyltransferase Activity in Caco-2 Cells. Drug Metabolism and Disposition, 2011, 39, 456-464.	3.3	18
117	Fluorescence-Based High-Throughput Screening Assay for Drug Interactions with UGT1A6. Assay and Drug Development Technologies, 2011, 9, 496-502.	1.2	7
118	Multifunctional Porous Silicon for Therapeutic Drug Delivery and Imaging. Current Drug Discovery Technologies, 2011, 8, 228-249.	1.2	97
119	In vitro cytotoxicity of porous silicon microparticles: Effect of the particle concentration, surface chemistry and size. Acta Biomaterialia, 2010, 6, 2721-2731.	8.3	158
120	Feasibility Evaluation of 3 Automated Cellular Drug Screening Assays on a Robotic Workstation. Journal of Biomolecular Screening, 2010, 15, 30-41.	2.6	10
121	Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Expert Opinion on Drug Delivery, 2010, 7, 705-719.	5.0	123
122	Cytotoxicity study of ordered mesoporous silica MCM-41 and SBA-15 microparticles on Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 483-494.	4.3	87
123	Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. Journal of Pharmacy and Pharmacology, 2010, 62, 1569-1579.	2.4	296
124	Biocompatibility of Thermally Hydrocarbonized Porous Silicon Nanoparticles and their Biodistribution in Rats. ACS Nano, 2010, 4, 3023-3032.	14.6	316
125	Solvent-Mediated Solid Phase Transformations of cArbamazepine: Effects of Simulated Intestinal Fluid and Fasted State Simulated Intestinal Fluid. Journal of Pharmaceutical Sciences, 2009, 98, 985-996.	3.3	49
126	Electrospray Encapsulation of Hydrophilic and Hydrophobic Drugs in Poly(<scp>L</scp>â€lactic acid) Nanoparticles. Small, 2009, 5, 1791-1798.	10.0	134

#	Article	IF	Citations
127	Mesoporous Silicon in Drug Delivery Applications. Journal of Pharmaceutical Sciences, 2008, 97, 632-653.	3.3	398
128	Drug release characteristics of physically crossâ€linked thermosensitive poly(Nâ€vinylcaprolactam) hydrogel particles. Journal of Pharmaceutical Sciences, 2008, 97, 4783-4793.	3.3	93
129	Quantitative determination of drug encapsulation in poly(lactic acid) nanoparticles by capillary electrophoresis. Journal of Chromatography A, 2008, 1178, 248-255.	3.7	34
130	Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices. International Journal of Pharmaceutics, 2008, 363, 66-72.	5.2	18
131	Feasibility of silicon and silica based mesoporous materials for oral drug delivery applications. European Journal of Pharmaceutical Sciences, 2008, 34, S21.	4.0	4
132	In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. Journal of Controlled Release, 2008, 126, 10-16.	9.9	71
133	The Expression of Most UDP-Glucuronosyltransferases (UGTs) Is Increased Significantly during Caco-2 Cell Differentiation, whereas UGT1A6 Is Highly Expressed Also in Undifferentiated Cells. Drug Metabolism and Disposition, 2008, 36, 2331-2336.	3.3	24
134	Physicochemical Characterization of Nano- and Microparticles. Current Nanoscience, 2008, 4, 101-107.	1.2	32
135	Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenetics and Genomics, 2007, 17, 115-126.	1.5	61
136	Enhanced in vitro permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 348-356.	4.3	83
137	Failure of MTT as a Toxicity Testing Agent for Mesoporous Silicon Microparticles. Chemical Research in Toxicology, 2007, 20, 1913-1918.	3.3	129
138	Cellâ€“polymer interactions of fluorescent polystyrene latex particles coated with thermosensitive poly(N-isopropylacrylamide) and poly(N-vinylcaprolactam) or grafted with poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 297 Td (c	6.2	41
139	Mechanistic evaluation of factors affecting compound loading into ion-exchange fibers. European Journal of Pharmaceutical Sciences, 2007, 31, 306-317.	4.0	20
140	Evaluation of cocktail approach to standardise Caco-2 permeability experiments. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 64, 379-387.	4.3	35
141	Freeze-Drying of Low Molecular Weight Poly(L-lactic acid) Nanoparticles: Effect of Cryo- and Lyoprotectants. Journal of Nanoscience and Nanotechnology, 2006, 6, 3110-3117.	0.9	29
142	In Situ Measurement of Solvent-Mediated Phase Transformations During Dissolution Testing. Journal of Pharmaceutical Sciences, 2006, 95, 2730-2737.	3.3	87
143	Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam). Biomaterials, 2005, 26, 3055-3064.	11.4	594
144	KINETIC CHARACTERIZATION OF THE 1A SUBFAMILY OF RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES. Drug Metabolism and Disposition, 2005, 33, 1017-1026.	3.3	85

#	Article	IF	Citations
145	Topical Iontophoretic Delivery. American Journal of Drug Delivery, 2005, 3, 67-81.	0.6	8
146	An Active and Water-Soluble Truncation Mutant of the Human UDP-Glucuronosyltransferase 1A9. Molecular Pharmacology, 2004, 65, 826-831.	2.3	22
147	Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis. European Journal of Pharmaceutical Sciences, 2004, 21, 371-377.	4.0	51
148	The interactions between the N-terminal and C-terminal domains of the human UDP-glucuronosyltransferases are partly isoform-specific, and may involve both monomers. Biochemical Pharmacology, 2004, 68, 2443-2450.	4.4	42
149	Nanoparticles containing ketoprofen and acrylic polymers prepared by an aerosol flow reactor method. AAPS PharmSciTech, 2004, 5, 129-137.	3.3	31
150	Formation and characterization of three-component-sorbitan monoester surfactant, oil and water-creams. International Journal of Pharmaceutics, 2004, 269, 227-239.	5.2	16
151	Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech, 2004, 5, 115-120.	3.3	35
152	N-in-one permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharmaceutical Research, 2003, 20, 187-197.	3.5	36
153	Dissolution testing of acetylsalicylic acid by a channel flow methodâ€"correlation to USP basket and intrinsic dissolution methods. European Journal of Pharmaceutical Sciences, 2003, 19, 395-401.	4.0	26
154	Rate and extent of ion-exchange process: the effect of physico-chemical characteristics of salicylate anions. Journal of Controlled Release, 2003, 91, 449-463.	9.9	27
155	Drug Adsorption in Human Skin: A Streaming Potential Study. Journal of Pharmaceutical Sciences, 2003, 92, 2366-2372.	3.3	11
156	Development of LC/MS/MS Methods for Cocktail Dosed Caco-2 Samples Using Atmospheric Pressure Photoionization and Electrospray Ionization. Analytical Chemistry, 2003, 75, 5969-5977.	6.5	87
157	Expression and Characterization of Recombinant Human UDP-glucuronosyltransferases (UGTs). Journal of Biological Chemistry, 2003, 278, 3536-3544.	3.4	134
158	Binding and release of drugs into and from thermosensitive poly(N-vinyl caprolactam) nanoparticles. European Journal of Pharmaceutical Sciences, 2002, 16, 69-74.	4.0	150
159	Improved stability and release control of levodopa and metaraminol using ion-exchange fibers and transdermal iontophoresis. European Journal of Pharmaceutical Sciences, 2002, 16, 273-280.	4.0	58
160	Rheological properties of three component creams containing sorbitan monoesters as surfactants. International Journal of Pharmaceutics, 2002, 247, 103-114.	5.2	33
161	Permeability profiles of M-alkoxysubstituted pyrrolidinoethylesters of phenylcarbamic acid across caco-2 monolayers and human skin. Pharmaceutical Research, 2002, 19, 162-168.	3.5	5
162	Transdermal iontophoresis of tacrine in vivo. Pharmaceutical Research, 2002, 19, 705-708.	3.5	54

#	Article	IF	Citations
163	The effect of cosolvents on the formulation of nanoparticles from low-molecular-weight poly(l)lactide. AAPS PharmSciTech, 2002, 3, E32.	3.3	62
164	Rheological properties of creams with four different surfactant combinations - effect of storage time and conditions. International Journal of Pharmaceutics, 2001, 221, 187-196.	5.2	76
165	The Behavior of Sorbitan Surfactants at the Waterâ€“Oil Interface: Straight-Chained Hydrocarbons from Pentane to Dodecane as an Oil Phase. Journal of Colloid and Interface Science, 2001, 240, 272-276.	9.4	104
166	Ion-exchange fibers and drugs: an equilibrium study. Journal of Controlled Release, 2001, 70, 219-229.	9.9	76
167	Influence of lipids on the mannitol flux during transdermal iontophoresis in vitro. European Journal of Pharmaceutical Sciences, 2000, 10, 97-102.	4.0	26
168	Controlled transdermal iontophoresis by ion-exchange fiber. Journal of Controlled Release, 2000, 67, 179-190.	9.9	73
169	Experimental verification of the mechanistic model for transdermal transport including iontophoresis. Journal of Controlled Release, 1998, 56, 169-174.	9.9	17
170	Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. , 1997, 14, 1258-1263.		70
171	Transdermal delivery of peptides by iontophoresis. Nature Biotechnology, 1996, 14, 1710-1713.	17.5	62
172	Transdermal penetration enhancers in rabbit pinna skin: Duration of action, skin irritation, and in vivo/in vitro comparison. International Journal of Pharmaceutics, 1993, 99, 253-261.	5.2	28
173	Transdermal iontophoresis of sotalol and salicylate; the effect of skin charge and penetration enhancers. Journal of Controlled Release, 1993, 26, 109-117.	9.9	28
174	Electrochemical characterization of human skin by impedance spectroscopy: the effect of penetration enhancers. Pharmaceutical Research, 1993, 10, 381-385.	3.5	38
175	Dodecyl N,N-dimethylamino acetate and azone enhance drug penetration across human, snake, and rabbit skin. Pharmaceutical Research, 1991, 08, 933-937.	3.5	59